Aim: The present study was designed to investigate the expression of Polo-like kinase 1 (PLK1) and survivin in non-Hodgkin's lymphoma (NHL). Methods: The expression of PLK1 and survivin were detected with immunohistochemical techniques. Results: The expression rate of PLK1 and survivin were 63.6% (56/88) and 79.5% (70/88) in NHL, respectively. PLK1 expression correlated with systemic symptoms, lactate dehydrogenase levels, and international prognostic index scores in B-NHL and T-NHL, while survivin did not. Conclusion: PLK1 and survivin are both overexpressed in NHL. There is a significant relationship between the overexpression of PLK1 and clinical features.
Introduction
Non-Hodgkin's lymphoma (NHL) forms a highly heterogeneous group of diseases. Despite steady improvement in their classification, patients with the same diagnosis can have markedly different clinical courses. Since prognosis remains uncertain, several biologically-based prognostic indicators have been proposed in addition to the international prognostic index (IPI) scores. However, none have proven to be completely effective [1] , so novel independent factors are required to better characterize the malignant potential of NHL. Accumulating evidence suggests that abnormalities in cell cycle and apoptosis are hallmarks of clonal expansion leading to cancer emergence [2, 3] . Polo-like kinase 1 (PLK1) has been implicated in various aspects of the progression of the cell cycle [4] , including centrosome maturation [5] , assembly of the mitotic spindle [6] , regulation of the anaphasepromoting complex [7] , and cytokinesis [8] . Survivin, a new inhibitor of the apoptosis protein (IAP) family, directly inhibits caspase 3 and caspase 7 and is one of the strongest anti-apoptosis factors by far [9] . Although PLK1 and survivin play completely different roles, they have some characteristics in common [10] [11] [12] [13] : they are mostly expressed in the G2/M phase of the cell cycle and they are not expressed in most normal differentiated tissues; however, they are overexpressed in a broad spectrum of cancer types and the expression often correlates with poor outcomes. To assess the clinical significance of PLK1 and survivin in NHL, the expression of PLK1 and survivin were examined and correlated with clinical outcome. follow-up data were available for all patients. The median follow up was 33 months (from 2 to 64 months). As a control for NHL, 5 cases of reactive lymph node proliferation were included in the study.
Materials and methods

Patients
Immunohistochemistry on tissue slides Immunostaining was performed with primary antibodies against PLK1 (1:100; rabbit polyclonal antibody; Biolegend, San Diego, CA, USA) and survivin (1:150; rabbit polyclonal antibody; Neomarkers, Fremont, CA, USA). In brief, 4 µm thick formalin-fixed paraffin sections were dewaxed and rehydrated through a graded series of ethanols. After antigen retrieval with microwave heating, the sections were treated with 0.3% hydrogen peroxide followed by incubation in bovine serum albumin. The sections were then incubated with primary antibodies. After washing with phosphatebuffered saline, the sections were incubated with biotinylated anti-immunoglobulin G of the appropriate species and streptavidin peroxidase using a labeled streptavidin biotin kit (Zhongshan Biotechnology, Beijing, China). The immunoperoxidase reaction product was visualized with diaminobenzidine/hydrogen peroxide. The sections were counterstained with hematoxylin.
Evaluation of tissue staining The staining intensity of the tissue slides was evaluated independently by 2 pathologists who were blinded to the patients' characteristics and survival. To assess the differences in staining intensity, an immunoreactivity scoring system (IRS) was applied. The intensity of staining was designated as negative (0), weak (1), moderate (2), or strong (3). Additionally, the percentage of positive cells was evaluated and scored as either no cells (0), less then 10% of cells (1), 10%-50% of cells (2), 51%-80% of cells (3), or over 80% of the cells stained (4) . By multiplication of these 2 parameters, the IRS for each case was calculated. Finally, the cases were grouped as antigen negative (IRS 0-6) or antigen positive (IRS 7-12) for statistical analysis [15] . 
Results
Expression of 2 proteins in NHL
In all 88 NHL cases, 63.6% expressed PLK1 and 79.5% expressed survivin. The detailed distribution is listed in Table 1 . The expression of PLK1 and survivin were then investigated in B-NHL and T-NHL, respectively. The PLK1 expression rate had no significance difference between B-NHL and T-NHL (57.8% vs 77.3%; P=0.103), as did survivin (76.6% vs 86.4%; P=0.544).
PLK1 was often strongly expressed in nuclei and seldom weakly in cytoplasm, while survivin was mainly strongly expressed in nuclei. None of the 5 reactive lymph node proliferation cases showed sufficient staining of PLK1 or survivin to be designated as positive (Figures 1, 2) .
Relationship between the expression of 2 proteins and clinical characteristics in B-NHL and T-NHL In B-NHL, there was a highly significant positive correlation of PLK1 expression with age, Ann Arbor stage, lactate de- hydrogenase (LDH) levels, systemic symptoms, IPI scores, and therapeutic effect. However, in T-NHL, the PLK1 expression was only associated with LDH levels, systemic symptoms, and IPI scores. There were no significant relationships between the survivin expression and these outcomes in either B-NHL or T-NHL (Table 2) .
Discussion
In recent years, a growing spectrum of biochemical investigations has contributed to better characterize biological tumor behavior, thereby improving treatment strategies [16] .
Among these studies, PLK1 and survivin were selected as the study objects, concerning the 2 important aspects of tumor biological behavior: proliferation and apoptosis. PLK1 is a cell cycle-regulated, cyclin-independent serine/threonine protein kinase, and its protein level changes from very low level during the G1 phase to at least a 10-fold increase by the G2/M phase [17] . PLK1 is involved in mitotic spindle organization and cytokinesis and seems to play an essential role in regulating chromosomal segregation [18] . Furthermore, overexpressed PLK1 can cause the formation of oncogenic foci in NIH 3T3 cells, which are capable of forming tumors in nude mice [19] . The elevated expression of PLK1 had been found in non-small cell lung cancer [20] , squamous cell carcinoma of the head and neck [21] , esophageal cancer [22] , gastric cancer [23] , ovarian cancer [24] , endometrial cancer [25] , colon cancer [26] , breast cancer [27] , and malignant melanoma [28] , prostate [29] , papillary carcinoma [30] , and oropharyngeal carcinomas [31] . The expression of PLK1 was correlated with an adverse clinical outcome in some tumors. Survivin belongs to the IAP family and it suppresses apoptosis induced by Fas, Bax, caspases, and anticancer drugs [32] . Survivin is expressed in a strict cell cycle-dependent and tissue-restricted manner. It is expressed at high levels in the G2/M phase and in proliferating tissues [33] .
Overexpressed survivin can be detected in almost all human tumors and is correlated with poor prognosis [34] .
In the present study, the expression rate of PLK1 was lower in some less aggressive or indolent types, such as small lymphocytic lymphoma (SLL) and marginal zone B-cell lymphoma (MALT) than that in some more aggressive types, such as diffuse large B-cell lymphoma (DLBCL) and peropheral T-cell lymphoma unspecified (PTLU), while the expression rate of survivin seemed to have no such trend. This suggested that PLK1 overexpression was correlated with cell-proliferating activity, and survivin overexpression implied the common characterization of NHL: the dysregulation of apoptosis.
PLK1 overexpression was positively linked to age, Ann Arbor stage, LDH levels, systemic symptoms, IPI scores, and therapeutic effect in B-NHL, and was only linked to LDH levels, systemic symptoms, and IPI scores in T-NHL. The reason may be the highly heterogeneity and limited number of cases of T-NHL. There was no significant difference between the survivin-negative and -positive groups for these characteristics, either in B-NHL or in T-NHL. It verified again that apoptosis resistance may be the essence of NHL.
In conclusion, PLK1 and survivin were expressed at high levels in NHL cases, and PLK1 overexpression was associated with elderly patient, advanced tumor stage, systemic symptoms, elevated LDH levels, and poor therapeutic effect. The overexpression of survivin was not correlated with bad outcome. 
